As the active metabolite of Leflunomide, a potent disease-modifying antirheumatic drug, Teriflunomide-d4 can be used in the treatment of rheumatoid arthritis. LEF-M interferes with dendritic cell function
Teriflunomide-d4 can be intended for use as an internal standard for the quantification of Leflunomide metabolite by GC- or LC-mass spectrometry.
This stable-labeled internal standard of teriflunomide is suitable for critical quantitative applications in clinical and diagnostic testing such as therapeutic drug monitoring assays. Teriflunomide, also known as Aubagio, is the active metabolite of leflunomide, an immunosuppressive disease-modifying antirheumatic drug, used in active moderate-to-severe rheumatoid arthritis and psoriatic arthritis.
